Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Artiva Biotherapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Artiva Biotherapeutics, Inc.’s stock price such as:

• Artiva Biotherapeutics, Inc.’s current stock price and volume
• Why Artiva Biotherapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ARTV from analysts
• ARTV’s stock price momentum as measured by its relative strength

About Artiva Biotherapeutics, Inc. (ARTV)

Before we jump into Artiva Biotherapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Want to learn more about Artiva Biotherapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Artiva Biotherapeutics, Inc..

Artiva Biotherapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Artiva Biotherapeutics, Inc.’s stock price was $10.100.

Artiva Biotherapeutics, Inc. is down 3.16% from its previous closing price of $10.430.

During the last market session, Artiva Biotherapeutics, Inc.’s stock traded between $9.675 and $10.410. Currently, there are approximately 24.68 million shares outstanding for Artiva Biotherapeutics, Inc..

Artiva Biotherapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Artiva Biotherapeutics, Inc. Stock Price History

Artiva Biotherapeutics, Inc.’s (ARTV) price is currently up 4.12% so far this month.

During the month of July, Artiva Biotherapeutics, Inc.’s stock price has reached a high of $11.300 and a low of $8.750.

Over the last year, Artiva Biotherapeutics, Inc. has hit prices as high as $14.530 and as low as $2.220. Year to date, Artiva Biotherapeutics, Inc.’s stock is up 135.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Artiva Biotherapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Artiva Biotherapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Artiva Biotherapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Artiva Biotherapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Artiva Biotherapeutics, Inc. (ARTV) by visiting AAII Stock Evaluator.

Relative Price Strength of Artiva Biotherapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Artiva Biotherapeutics, Inc. has a weighted four-quarter relative price strength of 33.91%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Artiva Biotherapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Artiva Biotherapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Artiva Biotherapeutics, Inc.’s stock price is $10.100, which is down 3.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Artiva Biotherapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.